Background The aim of this study was to observe the effects of neoadjuvant therapy with
irinotecan and5-fluorouracil (5-FU)/folinic acid (FA) on the resection rate and survival of …

Background Erdafitinib, a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase
inhibitor, was shown to be clinically active and tolerable in patients with advanced urothelial …

Diarrhoea is one of the most burdensome and common adverse events of chemotherapeutics,
and has no standardised therapy to date. Increasing evidence suggests that the gut …

We have previously reported that neoadjuvant therapy with modified FOLFIRI enabled nearly
a third of patients with metastatic colorectal cancer (mCRC) to undergo surgical resection …

Systemic inflammation has been proved to play a crucial role in promoting cancer progression
and metastasis in many cancer types, including colorectal cancer (CRC). The aim of the …

Melanoma is an extremely aggressive tumor and is considered to be an extremely
immunogenic tumor because compared to other cancers it usually presents a well-expressed …

Background: The World Health Organization (WHO) and the American Joint Cancer Committee
(AJCC) modified the grading of pancreatic neuroendocrine neoplasms from a three-tier (…

Estrogen receptor (ER), progesterone receptor (PR), and HER2/neu are the most important
tissue markers in the management of breast cancer, in the adjuvant setting and in the setting …

Simple Summary Survival after diagnosis of metastatic uveal melanoma has not significantly
improved over decades, most patients die within a year from diagnosis. Uveal melanoma is …

Background No standard treatment has been defined for metastatic uveal melanoma (mUM).
Although clinical trials testing Nivolumab/Pembrolizumab for cutaneous melanoma did not …